Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Reexamination Certificate
2011-03-01
2011-03-01
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
C560S157000
Reexamination Certificate
active
07897639
ABSTRACT:
Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure:wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.
REFERENCES:
patent: 3600427 (1971-08-01), Verbiscar
patent: 4791107 (1988-12-01), Hamer et al.
patent: 4948807 (1990-08-01), Rosin et al.
patent: 5187165 (1993-02-01), Hamer et al.
patent: 5302721 (1994-04-01), Wong et al.
patent: 5409948 (1995-04-01), Greig et al.
patent: 5455354 (1995-10-01), Wong et al.
patent: 5538968 (1996-07-01), Chiesi et al.
patent: 5602176 (1997-02-01), Enz
patent: 5665880 (1997-09-01), Lee et al.
patent: 5677457 (1997-10-01), Lee et al.
patent: 2007/0275959 (2007-11-01), Verheijen et al.
patent: 2002226687 (2002-08-01), None
patent: 38 05 744 (1988-09-01), None
patent: 0513703 (1992-11-01), None
patent: 2 719 047 (1995-10-01), None
patent: 03002155 (1991-01-01), None
patent: WO 96/02524 (1996-02-01), None
patent: WO 97/14694 (1997-04-01), None
patent: WO-97/22339 (1997-06-01), None
patent: WO 97/23484 (1997-07-01), None
patent: WO-00/25821 (2000-05-01), None
patent: WO-2004/034963 (2004-04-01), None
White et al. “On the Physostigmine-Like Action of Certain Synthetic Urethanes” J. Pharmacol. 1931, vol. 41, pp. 259-288.
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews, 1996, vol. 96, pp. 3147-3176.
Tumiatti et al. “[4-[[N-(3-Chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium (McN-A-343)-Related Compounds. Effect on the Butynyl Chain Inclusion into an Aromatic Unit on the Potency for Muscarinic Receptors” Bioorganic & Medicinal Chemistry, 2000, vol. 8, pp. 681-689.
Amstutz et al., “Cyclische Phenyl-carbamate des Miotin-Typs und ihre Wirkung auf die Acetylcholinesterase”,Helvetica Chimica Acta, 73:739-753 (1990) (English Abstract Only).
Brossi et al., “Invited Review. Phenserine, a Novel Anticholinesterase Related to Physostigmine: Total Synthesis and Biological Properties”,Aust. J. Chem., 49:171-181 (1996).
Cutler et al., “Muscarinic M1-Receptor Agonists: Potential in the Treatment of Alzheimer's Disease”,CNS Drugs, 3(6):467-481 (1995).
Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, Koyama et al., “Pharmaceuticals containing (hydroxybenzyl) amines as acetylcholine esterase inhibitors and selective serotonin reuptake inhibitors”, XP002331878 retrieved from STN Database accession No. 2004:291183 abstract & JP 2004 107322 A2 (BTG International Ltd., UK) Apr. 8, 2004.
Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, Goto et al., “Preparation of aromatic carbamates as choline esterase inhibitors for improvement of cerebral function”, XP002331879 retrieved from STN Database accession No. 1991:206818 abstract & JP 03 002155 A2 (Takeda Chemical Industries, Ltd., Japan) Jan. 8, 1991.
Database Beilstein, Beilstein Institut Fuer Chemische Wissenschaften, Frankfurt Am Main, DE, XP002331880.
De Sarno et al., “The Effect of Heptyl-Physostigmine, a New Cholinesterase Inhibitor, on the Central Cholinergic System of the Rat”,Neurochem. Res., 14(10):971-977 (1989).
Elmalem et al., “Antagonism of Morphine-Induced Respiratory Depression by Novel Anticholinesterase Agents”,Neuropharmacol., 30(10):1059-1064 (1991).
Froestl et al., “SGS742: the first GABABreceptor antagonist in clinical trials”,Biochem. Pharmacol., 68:1479-1487 (2004).
Gatto et al., “TC-1734: An Orally Active Neuronal Nicotinic Acetylcholine Receptor Modulator with Antidepressant, Neuroprotective and Long-Lasting Cognitive Effects”,CNS Drug Reviews, 10(2):147-166 (2004).
Heinonen et al., “Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans”,J. Clin. Pharmacol., 37:602-609 (1997).
Janssen et al., “Does phenylethylamine act as an endogenous amphetamine in some patients?”,Int. J. Neuropsychopharmacol., 2:229-240 (1999).
Kerr et al., “GABABReceptors”,Pharmac. Ther., 67(2):187-246 (1995).
Korczyn, A.D., “Muscarinic M1agonist in the treatment of Alzheimer's disease”,Exp. Opin. Invest. Drugs, 9(10):2259-2267 (2000).
Kupsch, A., “Rasagiline Teva Pharmaceutical”,Curr. Opin. Investig. Drugs, 3(5):794-979 (2002).
Land et al., “D-Cycloserine: Effects on Long-Term Retention of a Conditioned Response and on Memory for Contextual Attributes”,Neurobiol. Learning Mem., 72(3):158-168 (1999).
Lipiello et al., “RJR-2403 is an Efficacious Agonist for Human β4α2 Neuronal Nicotinic Acetylcholine Receptors with Lower Efficacy for Other Human Receptor Subtypes”,Soc. Neurosci., 24:88 (Abstract 39.26) (1998).
Obinu et al., “Brain Selective Stimulation of Nicotinic Receptors by RJR 1734 Enhances ACh Transmission From Frontoparietal Cortex and Enhances Memory in Rodents”,Internatl. J. Neuropyschopharamology, 3(Suppl. 1):S361 (2003) (Abstract Only).
Obinu et al., “Brain Selective Stimulation of Nicotinic Receptors by TC-1734 Enhances Ach Transmission From Frontoparietal Cortex and Enhances Memory in Rodents”,Progress Neuropsychopharmacol. Biol. Psychiatry, 26:913-918 (2002).
Parsons et al., “Memantine is a clinically well toleratedN-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data”,Neuropharmacol., 38(5):735-767 (1999).
Rampa et al., “Acetylcholinesterase Inhibitors: SAR and Kinetic Studies on ω-[N-Methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl Derivatives”,J. Med. Chem., 44:3810-3820 (2001).
Sterling et al., “Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease”,J. Med. Chem., 45:5260-5279 (2002).
Trabace et al., “CHF2819: Pharmacological Profile of a Novel Acetylcholinesterase Inhibitor”,CNS Drug Reviews, 8(1):53-69 (1992).
Tumiatti et al., “[4-[[N-(3-Chlorophenyl)carbamoyl]oxy]-2-butynyl]-trimethylammonium (McN-A-343)-Related Compounds. Effect of the Butynyl Chain Inclusion into an Aromatic Unit on the Potency for Muscarinic Receptors”,Bioorg. Med. Chem., 8:681-689 (2000).
Yang et al., “β-Phenylethylamine: A Specific Substrate for Type B Monoamine Oxidase of Brain”,J. Pharmacol. Exp. Ther., 187(2):365-371 (1973).
Fogelson et al., “Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients”,Acta Neurol. Scand., 107(4):252-255 (2003).
Grace et al., “A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease”,Int J. Geriatr. Psychiatry, 15(11):1028-1033 (2000).
Schredl et al., “The effect of rivastigmine on sleep in elderly healthy subjects”,Experimental Gerontol., 35(2):243-249 (2000).
Siatra-Papastaikoudi, T., et al., “Synthesis of Carbamate Esters of Phenethylamines and their Pharmacological Action on the Central Nervous System”,Chimika Chronika, 10(4), 307-13 (1981).
Du ShouCheng
Verheijen Jeroen C.
CoLucid Pharmaceuticals, Inc.
Elrifi Ivor R.
Erlacher Heidi A.
Kosack Joseph R
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Carbamoyl esters that inhibit cholinesterase and release... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamoyl esters that inhibit cholinesterase and release..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamoyl esters that inhibit cholinesterase and release... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665424